"An opportunity we should embrace," ABPI on RCP report

2 March 2009

Richard Tiner, the Association of the British Pharmaceutical Industry's medical director, has responded to media claims that the  Royal College of Physicians' recent report (Innovating for Health;  Marketletter February 16) "is just the latest in a line of attacks" on  drugmakers. Dr Tiner argues that the RCP "wants to re-invigorate the  relationship between the people that make medicines and the people that  prescribe them" for a "new covenant" by removing gift and  pharma-sponsored continuing education for physicians. Common ground  exists in other areas, such as drug access to patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight